Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1886 1
1890 1
1924 1
1951 1
1952 2
1960 1
1962 1
1963 1
1966 1
1967 1
1968 1
1970 1
1973 1
1977 2
1978 1
1979 2
1980 1
1981 2
1982 1
1984 1
1987 1
1989 1
1990 1
1991 1
1992 4
1993 3
1994 2
1995 7
1996 11
1997 7
1998 8
1999 6
2000 8
2001 9
2002 10
2003 16
2004 10
2005 9
2006 16
2007 16
2008 24
2009 17
2010 22
2011 19
2012 26
2013 23
2014 12
2015 25
2016 26
2017 28
2018 17
2019 19
2020 24
2021 19
2022 11
2023 16
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

443 results

Results by year

Filters applied: . Clear all
Page 1
Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial.
Hutchings M, Morschhauser F, Iacoboni G, Carlo-Stella C, Offner FC, Sureda A, Salles G, Martínez-Lopez J, Crump M, Thomas DN, Morcos PN, Ferlini C, Bröske AE, Belousov A, Bacac M, Dimier N, Carlile DJ, Lundberg L, Perez-Callejo D, Umaña P, Moore T, Weisser M, Dickinson MJ. Hutchings M, et al. Among authors: crump m. J Clin Oncol. 2021 Jun 20;39(18):1959-1970. doi: 10.1200/JCO.20.03175. Epub 2021 Mar 19. J Clin Oncol. 2021. PMID: 33739857 Free PMC article. Clinical Trial.
Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12.
Crump M, Kuruvilla J, Couban S, MacDonald DA, Kukreti V, Kouroukis CT, Rubinger M, Buckstein R, Imrie KR, Federico M, Di Renzo N, Howson-Jan K, Baetz T, Kaizer L, Voralia M, Olney HJ, Turner AR, Sussman J, Hay AE, Djurfeldt MS, Meyer RM, Chen BE, Shepherd LE. Crump M, et al. J Clin Oncol. 2014 Nov 1;32(31):3490-6. doi: 10.1200/JCO.2013.53.9593. Epub 2014 Sep 29. J Clin Oncol. 2014. PMID: 25267740 Free article. Clinical Trial.
Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma.
Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Reagan PM, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Crump M, Kuruvilla J, Van Den Neste E, Farooq U, Navale L, DePuy V, Kim JJ, Gisselbrecht C. Neelapu SS, et al. Among authors: crump m. Blood Adv. 2021 Oct 26;5(20):4149-4155. doi: 10.1182/bloodadvances.2020003848. Blood Adv. 2021. PMID: 34478487 Free PMC article.
Portfolio and prosper.
Crump MJC. Crump MJC. Nat Hum Behav. 2019 Oct;3(10):1008. doi: 10.1038/s41562-019-0689-0. Nat Hum Behav. 2019. PMID: 31602021 No abstract available.
Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study.
O'Connor OA, Pro B, Pinter-Brown L, Bartlett N, Popplewell L, Coiffier B, Lechowicz MJ, Savage KJ, Shustov AR, Gisselbrecht C, Jacobsen E, Zinzani PL, Furman R, Goy A, Haioun C, Crump M, Zain JM, Hsi E, Boyd A, Horwitz S. O'Connor OA, et al. Among authors: crump m. J Clin Oncol. 2011 Mar 20;29(9):1182-9. doi: 10.1200/JCO.2010.29.9024. Epub 2011 Jan 18. J Clin Oncol. 2011. PMID: 21245435 Free PMC article. Clinical Trial.
Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial.
O'Connor OA, Lue JK, Sawas A, Amengual JE, Deng C, Kalac M, Falchi L, Marchi E, Turenne I, Lichtenstein R, Rojas C, Francescone M, Schwartz L, Cheng B, Savage KJ, Villa D, Crump M, Prica A, Kukreti V, Cremers S, Connors JM, Kuruvilla J. O'Connor OA, et al. Among authors: crump m. Lancet Oncol. 2018 Feb;19(2):257-266. doi: 10.1016/S1470-2045(17)30912-9. Epub 2017 Dec 21. Lancet Oncol. 2018. PMID: 29276022 Free PMC article. Clinical Trial.
Measuring Adaptive Control in Conflict Tasks.
Braem S, Bugg JM, Schmidt JR, Crump MJC, Weissman DH, Notebaert W, Egner T. Braem S, et al. Among authors: crump mjc. Trends Cogn Sci. 2019 Sep;23(9):769-783. doi: 10.1016/j.tics.2019.07.002. Epub 2019 Jul 19. Trends Cogn Sci. 2019. PMID: 31331794 Free PMC article. Review.
Cost-Effectiveness Analysis of Frontline Polatuzumab-Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone and/or Second-Line Chimeric Antigen Receptor T-Cell Therapy Versus Standard of Care for Treatment of Patients With Intermediate- to High-Risk Diffuse Large B-Cell Lymphoma.
Vijenthira A, Kuruvilla J, Crump M, Jain M, Prica A. Vijenthira A, et al. Among authors: crump m. J Clin Oncol. 2023 Mar 10;41(8):1577-1589. doi: 10.1200/JCO.22.00478. Epub 2022 Oct 31. J Clin Oncol. 2023. PMID: 36315922
443 results